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John E. Hall
OBJECTIVE—We recently showed that leptin has powerful
central nervous system (CNS)-mediated antidiabetic and cardio-
vascular actions. This study tested whether the CNS melanocor-
tin system mediates these actions of leptin in diabetic rats.
RESEARCH DESIGN AND METHODS—A cannula was
placed in the lateral ventricle of Sprague-Dawley rats for intra-
cerebroventricular infusions, and arterial and venous catheters
were implanted to measure mean arterial pressure (MAP) and
heart rate 24 h/day and for intravenous infusions. After recovery
from surgery for 8 days, rats were injected with streptozotocin
(STZ), and 5 days later, either saline or the melanocortin 3 and 4
receptor (MC3/4R) antagonist SHU-9119 (1 nmol/h) was infused
intracerebroventricularly for 17 days. Seven days after starting
the antagonist, leptin (0.62 g/h) was added to the intracerebro-
ventricular infusion for 10 days. Another group of diabetic rats
was infused with the MC3/4R agonist MTII (10 ng/h i.c.v.) for 12
days, followed by 7 days at 50 ng/h.
RESULTS—Induction of diabetes caused hyperphagia, hyper-
glycemia, and decreases in heart rate (76 bpm) and MAP (7
mmHg). Leptin restored appetite, blood glucose, heart rate, and
MAP back to pre-diabetic values in vehicle-treated rats, whereas
it had no effect in SHU-9119–treated rats. MTII infusions tran-
siently reduced blood glucose and raised heart rate and MAP,
which returned to diabetic values 5–7 days after starting the
infusion.
CONCLUSIONS—Although a functional melanocortin system is
necessary for the CNS-mediated antidiabetic and cardiovascular
actions of leptin, chronic MC3/4R activation is apparently not
sufﬁcient to mimic these actions of leptin that may involve
interactions of multiple pathways. Diabetes 58:1749–1756,
2009
L
eptin, an adipocyte-derived peptide that circu-
lates in proportion to the amount of body fat, is
well known for its role in body weight homeosta-
sis (1–3). Leptin informs the brain of the body’s
energy storage status and promotes weight loss by reduc-
ing appetite and increasing energy expenditure by stimu-
lation of sympathetic nervous system activity to various
tissues, including brown adipose tissue (4,5). In addition
to its role in body weight homeostasis, leptin exerts
important cardiovascular actions that are mediated via the
central nervous system (CNS). For example, studies from
our laboratory and others indicate that leptin may be an
important link between excess weight gain and increased
arterial pressure (6–9). Chronic hyperleptinemia in lean
animals raises arterial pressure, whereas leptin deﬁciency
causes severe obesity and many features of the metabolic
syndrome without the accompanying hypertension (7–10).
Leptin also stimulates glucose utilization in peripheral
tissues by activating CNS pathways. We recently showed
that chronic intracerebroventricular infusion of leptin in
diabetic rats completely restored blood glucose to normal
levels and prevented the hyperphagia and the marked
bradycardia associated with streptozotocin (STZ)-induced
diabetes (11). These observations indicate that the power-
ful effects of leptin on glucose regulation and cardiovas-
cular function in insulin-deﬁcient diabetic rats are
mediated, mainly by leptin’s direct actions on the CNS, and
are independent of insulin. However, the CNSs mecha-
nisms that mediate leptin’s chronic effects on glucose
homeostasis and cardiovascular function are still unclear.
Leptin has been shown to suppress several orexigenic
pathways including neuropeptide Y (NPY), agouti-related
peptide (AGRP), and melanin-concentrating hormone, while
activating anorexigenic pathways such as corticotrophin-
releasing hormone, cocaine-amphetamine–related peptide,
and the proopiomelanocortin (POMC) system (1–3,12–20).
Among these factors, the POMC pathway appears to play
a key role in mediating the appetite and cardiovascular
CNS actions of leptin. Leptin-mediated stimulation of the
POMC neurons leads to release of -melanocyte stimulat-
ing hormone (-MSH) and activation of the melanocortin 3
and 4 receptors (MC3/4R) in several brain nuclei (1,12).
Activation of MC3/4R has been demonstrated to contribute
importantly to the anorexic actions of leptin (13–15), while
absence of functional melanocortin system, either by
pharmacological blockade of the MC3/4R (9,16,17) or
genetic disruption of the MC4R (18), results in complete
unresponsiveness to the chronic blood pressure and heart
rate effects of leptin. Acute and chronic studies also
suggest that activation of the MC3/4R improves insulin
sensitivity and that blockade of the MC3/4R causes
marked insulin resistance (20–22). However, the role of
the CNS melanocortin system in mediating the chronic
antidiabetic and cardiovascular actions of leptin in insulin-
deﬁcient diabetes are still unknown.
In this study, we demonstrate that activation of the
MC3/4R is required for leptin to exert its chronic antidia-
betic and cardiovascular actions. Our results also indicate,
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DIABETES, VOL. 58, AUGUST 2009 1749however, that chronic stimulation of the MC3/4R alone,
using a pharmacological agonist, causes only transient
reductions in blood glucose in diabetic rats. These obser-
vations suggest that a functional melanocortin system is
necessary for the CNS-mediated antidiabetic and cardio-
vascular actions of leptin, but chronic MC3/4R activation
is apparently not sufﬁcient to mimic these actions of leptin
that may involve interactions of multiple pathways.
RESEARCH DESIGN AND METHODS
Animal surgeries. The experimental procedures and protocols of this study
conformed to the National Institutes of Health Guide for the Care and Use of
Laboratory Animals and were approved by the Institutional Animal Care and
Use Committee of the University of Mississippi Medical Center.
Intra-arterial and intravenous catheterization. Male Sprague-Dawley
(Harlan, Indianapolis, IN) rats (325–350 g, n  20) were anesthetized with 50
mg/kg sodium pentobarbital (Nembutal), and atropine sulfate (0.1 mg/kg) was
administered to prevent excess airway secretions. Arterial and venous cath-
eters were implanted according to procedures previously described (11,22).
Brieﬂy, using aseptic techniques, a laparotomy was performed and a sterile
nonocclusive polyvinyl catheter was inserted into the abdominal aorta, distal
to the kidneys. Through a left femoral vein incision, a sterile catheter was
placed in the vena cava. Both catheters were exteriorized through a subcuta-
neously implanted stainless steel button.
Intracerebroventricular cannulation. Immediately after arterial and ve-
nous catheter implantation, a stainless steel cannula (26 gauge, 10 mm long)
was implanted into the right lateral cerebral ventricle using the coordinates
previously described (22). The guide cannula was anchored into place with
three stainless steel machine screws, a metal cap, and dental acrylic, and a
stylet was inserted to seal the cannula until use. During stereotaxic manipu-
lation, anesthesia was maintained with 0.5–1.5% isoﬂuorane. After 7 days of
recovery from surgery, accuracy of the cannula placement was tested by
measuring the dipsogenic response (immediate drinking of at least 5 ml of
water in 10 min) to an intracerebroventricular injection of 100 ng angiotensin
II. After the experiment, the animals were killed and the brains removed and
sectioned to conﬁrm placement of the cannula.
After recovery from anesthesia, the rats were housed in individual meta-
bolic cages for determination of daily water and food consumption. The
arterial and venous catheters were connected to a dual-channel infusion
swivel (Instech). The arterial catheter was connected to a pressure transducer
(Maxxim) for continuous 24-h measurement of mean arterial pressure (MAP)
and heart rate using computerized techniques as previously described (7,8).
The venous catheter was connected to a syringe pump for continuous infusion
of saline (0.45%, 40 ml/day). The rats received food and water ad libitum
throughout the study. Total sodium intake was maintained constant at 3.1
mEq/day via the continuous saline infusion combined with sodium-deﬁcient
rat chow (0.006 mmol sodium/g food, Teklad). Intravenous solutions were
infused through a sterile ﬁlter (0.22 m, Millipore), and the saline infusion was
started immediately after placement of the rats into the metabolic cages. The
rats were allowed to recover for 8–10 days before control measurements were
initiated.
Experimental protocols. MAP, heart rate, urine volume, food, and water
intake were measured 24 h/day and average values were recorded daily.
Induction of diabetes. After 4–5 days of stable control measurements,
insulin-deﬁcient diabetes was induced by a single intravenous injection of
streptozotocin (STZ, 50 mg/kg [Sigma Aldrich], dissolved in 0.5 ml of 0.05 M
citrate buffer, pH 4.5).
Chronic intracerebroventricular leptin infusion in diabetic rats (n 
5). Five days after STZ injection, leptin (0.62 g/h, 0.5 l/h) was infused
intracerebroventricularly for 10 days via osmotic minipump (model 2002,
Durect) implanted subcutaneously in the scapular region as previously
described (20). We have shown that this rate of leptin infusion fully restores
euglycemia in STZ-diabetic rats (11).
Chronic intracerebroventricular infusion of a MC3/4R agonist, MTII
(n  10). Five days after STZ injection, the MC3/4R agonist, MTII (10 ng/h, 0.5
l/h, Polypeptide Laboratories), was infused intracerebroventricularly for 10
days via osmotic minipump as described above (n  5). On the 10th day of
MTII infusion at 10 ng/h, the rats were lightly anesthetized with isoﬂuorane
and the osmotic minipump was replaced by another pump to deliver the
agonist at a higher concentration (50 ng/h).
In a separate experiment, diabetic rats (n  5) were treated with MTII at
the dose of 10 ng/h and were pair-fed the same amount of food consumed by
diabetic rats during chronic leptin intracerebroventricular infusion.
Chronic intracerebroventricular leptin infusion during MC3/4R block-
ade (n  5). Five days after STZ injection, the MC3/4R antagonist SHU-9119
(1 nmol/h, 0.5 l/h; Polypeptide Laboratories) was infused intracerebroven-
tricularly for 17 days via osmotic minipump as described above. After the ﬁrst
7 days of intracerebroventricular SHU-9119 infusion, an additional minipump
was implanted 1–2 cm apart from the other minipump and connected to the
intracerebroventricular cannula via a Y connector to deliver leptin intracere-
broventricularly for 10 days at 0.62 g/h. The rate of SHU-9119 infusion was
based on our previous study showing that this dose effectively blocks the
MC3/4R and the chronic dietary and cardiovascular effects of leptin in normal
Sprague-Dawley rats (9). Blood glucose concentration was measured each
morning between 9:00 and 10:00 A.M. for determination of blood glucose levels
using glucose strips (Reli On).
Statistical analysis. The data are expressed as mean  SE and analyzed by
using two-factor ANOVA with repeated measures. The Bonferroni post hoc
test was used for comparisons between groups. Dunnett’s test was used for
comparisons of experimental and control values within each group, when
appropriate. Statistical signiﬁcance was accepted at a level of P  0.05.
RESULTS
Effects of induction of diabetes and chronic intrace-
rebroventricular leptin infusion on appetite, blood
glucose, and cardiovascular function. Induction of in-
sulin-deﬁcient diabetes with STZ was associated with
rapid development of hyperglycemia (433  28 mg/100 ml
on day 5 post-STZ injection, Fig. 1B, Table 1), hyperphagia
(from 22  1 g/day in the control period to 45  2 g/day on
day 5 after STZ injection, Fig. 1A), and increased water
intake and urine volume (Table 1).
Induction of STZ-diabetes also caused marked bradycar-
dia with heart rate rapidly falling by as much as 77 bpm
5 days after STZ injection (Fig. 2A). MAP responses after
the induction of diabetes were variable among the groups
but remained unchanged on average during the ﬁrst 5 days
after induction of diabetes (Fig. 2B). We previously
showed that it takes 10–15 days after the STZ injection
for a signiﬁcant reduction in MAP (11).
Chronic intracerebroventricular leptin infusion for 10
days in diabetic rats decreased food intake from 45  2
g/day to an average of 16  1 g/day during the last 5 days
of leptin infusion (Fig. 1A) and reduced blood glucose
levels all the way back to pre-diabetic control values
(118  19 mg/100 ml, Fig. 1B, Table 1).
The normalization of blood glucose levels by intracere-
broventricular leptin infusion was accompanied by a
marked reduction in urine volume and water intake to
values similar to pre-diabetic levels (Table 1). In addition,
chronic leptin treatment reversed the bradycardia and
raised heart rate by 40–50 bpm above the pre-diabetic
control values (Fig. 2A). Although leptin tended to raise
MAP, the increase was not signiﬁcant compared with the
day before leptin infusion was started (Fig. 2B).
Effects of chronic intracerebroventricular infusion of
MC3/4R agonist on appetite, blood glucose, and car-
diovascular function. Chronic intracerebroventricular
infusion of the MC3/4R agonist, MTII, at a dose of 10 ng/h
for 10 days in ad libitum–fed diabetic rats caused only a
transient reduction in food intake lasting for 3–4 days,
after which food intake returned to values observed before
the MTII infusion was started (Fig. 1B). During the course
of the 10-day treatment period, food intake continued to
rise to a level that was more than double the initial control
level. A similar pattern was observed for the effects of
MTII on blood glucose levels, except for the less pro-
nounced initial reduction in glucose levels (Fig. 1A).
Chronic MC3/4R activation also resulted in a transient
reduction in water intake and urine output, in parallel with
the transient changes in blood glucose levels (Table 1).
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rats also attenuated the bradycardia associated with in-
duction of diabetes and raised heart rate by 50 bpm
during the initial 5 days of infusion (Fig. 2A). However, this
effect waned on days 6–7 of MTII infusion and heart rate
gradually fell. We also observed a 10-mmHg initial eleva-
tion in MAP during the ﬁrst 5–6 days of MTII infusion that
was followed by a return of MAP to the same values
observed on the day before MTII treatment was initiated
(Fig. 2B).
A ﬁvefold increase in the dose of MTII from 10–50 ng/h
had no additional effect to prevent the hyperphagia, hyper-
glycemia, and bradycardia associated with STZ-induced
diabetes (Fig. 1A and B). These results indicate that
chronic MC3/4R activation alone does not recapitulate the
long-term effects of leptin on food intake, glucose ho-
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FIG. 1. Food intake (A) and blood glucose (B) responses to chronic intracerebroventricular infusion of leptin (F, n  5) or the MC3/4R agonist
MTII in ad libitum–fed (, n  5) and pair-fed (Œ, n  5) STZ-diabetic rats. Data are means  SE.
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diabetes.
Inclusion of a group of pair-fed diabetic rats treated with
MTII to match the amount of food consumed by the
leptin-treated group showed no additional effects of the
pair-feeding on the long-term actions of MC3/4R activation
on appetite, glucose homeostasis, or cardiovascular func-
tion in STZ-diabetic rats (Fig. 1A and B, Table 1). These
results suggest that changes in food intake cannot explain
the lack of sustained long-term metabolic and cardiovas-
cular actions during MC3/4R activation.
Effects of chronic intracerebroventricular leptin
infusion on appetite, glucose levels, and cardiovascu-
lar function during MC3/4R antagonism. Although
chronic MTII intracerebroventricular infusion for 17 days
did not mimic the results observed in the leptin-treated
group, a functional MC3/4R is required for leptin to exert
its metabolic and cardiovascular effects in diabetic rats.
Chronic blockade of MC3/4R, using SHU-9119, completely
abolished the effects of leptin to reduce food intake and to
restore euglycemia in STZ-diabetic rats. Food intake re-
mained elevated at 57  2 g/day and blood glucose
averaged 436  14 mg/100 ml on day 10 of leptin plus
SHU-9119 intracerebroventricular infusion (Fig. 3A and B).
The inability of leptin to reduce blood glucose levels and
food consumption during MC3/4R antagonism was also
reﬂected in the maintenance of markedly elevated water
intake and urine output during intracerebroventricular
leptin infusion, in contrast to the effects of leptin to
completely restore these variables to pre-diabetic levels in
rats with intact MC3/4R function (Table 1).
In addition to preventing the antidiabetic and anorexic
actions of leptin, SHU-9119 treatment also abolished the
rise in heart rate during intracerebroventricular leptin
infusion; heart rate continued to fall during leptin treat-
ment (137  11 bpm on the last day of intracerebroven-
tricular leptin infusion, Fig. 4A). MC3/4R antagonism also
blocked leptin’s ability to prevent the fall in MAP normally
observed when STZ-induced diabetes is maintained for
periods longer than 2 weeks (92  3 vs. 80  3 mmHg for
control and the last day of intracerebroventricular leptin
infusion, respectively; Fig. 4B).
DISCUSSION
There are two major ﬁndings of this study. First, we
demonstrated that the chronic antidiabetic, appetite, and
cardiovascular actions of leptin in insulin-deﬁcient STZ-
diabetic rats require a functional CNS melanocortin sys-
tem and ultimately activation of MC3/4R; blockade of
these receptors completely prevented the chronic effects
of leptin on food and water intake, blood glucose, heart
rate, blood pressure, and urine volume. Second, chronic
MC3/4R activation alone transiently reduced appetite and
blood glucose while raising heart rate in diabetic rats, but
these effects gradually waned and did not mimic the
responses observed during chronic hyperleptinemia.
These results indicate that activation of the MC3/4R is
required for leptin to exert its metabolic and cardiovascu-
lar actions, but is apparently not sufﬁcient to mimic these
actions of leptin that may involve interactions of multiple
pathways.
It is likely that other systems are triggered during
prolonged MC3/4R stimulation to offset the reductions in
food intake and blood glucose as well as the MAP and
heart rate responses to MC3/4R activation. The identity of
these compensatory systems is still uncertain, but may
involve activation of orexigenic factors known to be
suppressed by leptin (i.e., NPY, melanin-concentrating
hormone, AGRP, and others) and/or downregulation of
anorexigenic factors that are stimulated by leptin (i.e.,
corticotrophin-releasing hormone, cocaine-amphetamine–
related peptide, and brain-derived neurotrophic factor, for
example). It is possible that leptin-induced changes in one
or more of these factors also contribute to the powerful
antidiabetic effect of leptin and additional studies will be
needed to answer these questions.
The observation that MC3/4R antagonism abolished the
antidiabetic and cardiovascular actions of leptin is consis-
tent with our previous ﬁnding that an intact hypothalamic
MC3/4R is necessary for leptin to reduce food intake and
fasting insulin levels and to raise heart rate and blood
pressure in normal nondiabetic rats (9). However, the
long-term responses to MC3/4R activation by MTII infu-
sion in STZ-diabetic rats differed from our previous obser-
vations in nondiabetic rats where, despite not causing
sustained reductions in food intake, the elevations in heart
rate and MAP were maintained through the entire period
of MTII treatment (22,23). Increasing the dose of MTII
ﬁvefold did not alter the responses when compared with
the lower dosage, indicating that the waning responses are
not likely to be caused by an insufﬁcient level of MC3/4R
activation in diabetic rats. One possible explanation for
these differences is that activation of compensatory mech-
anisms during chronic MC3/4R activation is even more
TABLE 1
Blood glucose, water intake, and urine output in STZ-diabetic
rats treated with leptin alone (0.62 g/h i.c.v.) or during MC3/4R
antagonism with SHU-9119 (1 nmol/h i.c.v.) and in diabetic rats
fed ad libitum or pair-fed that were infused with the MC3/4R
agonist MTII (10 ng/h i.c.v.)
Glucose
(mg/100 ml)
Water
intake
(ml/day)
Urine
output
(ml/day)
Leptin group
Control 99  58  24 5  2
STZ—day 5 433  28* 211  20* 161  21*
Leptin—day 10 118  19 6  35 4  4
MTII ad libitum group
Control 112  31 1  23 9  4
STZ—day 5 418  43* 139  16* 198  18*
MTII (10 ng/h)—day 2 319  53*† 42  15*† 83  22*†
MTII (10 ng/h)—day 10 401  18* 245  34*† 300  43*†
MTII (50 ng/h)—day 2 429  12* 159  23* 213  30*
MTII (50 ng/h)—day 7 423  13* 303  20*† 358  19*†
MTII pair-fed group
Control 97  61 2  24 5  3
STZ—day 5 449  20* 193  23* 241  18*
MTII (10 ng/h)—day 2 426  27* 141  32* 177  30*
MTII (10 ng/h)—day 10 401  19* 71  21*† 103  24*†
Leptin  SHU-9119 group
Control 114  49  14 1  3
STZ—day 5 442  42* 144  15* 189  18*
SHU-9119—day 7 440  21* 268  17*† 326  19*†
Leptin  SHU-9119—day 10 436  14* 350  34*† 419  37*†
Values expressed are for day 5 of control period, 5 days after
injection of STZ, and during the experimental periods as indicated in
the table. Note: Total daily ﬂuid intake equals the water plus a ﬁxed
continuous intravenous saline infusion (40 ml/day, 0.45% saline)
throughout the study. *P  0.05 compared with control; †P  0.05
compared with STZ—day 5.
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instance, in STZ-induced diabetes, NPY/AGRP neurons are
markedly activated and may play a major role in promot-
ing the hyperphagia in this model of diabetes (24,25).
Another possible explanation for the inability of chronic
MC3/4R activation to mimic the antidiabetic effects of
leptin is that MC3/4R may have only a short-term anorectic
action and that the initial fall in blood glucose is mainly
caused by a reduction in food intake. It could be hypoth-
esized that the hyperphagia in diabetes and increased
intake of glucose and other nutrients (fat and proteins)
that can be transformed into glucose overcomes the
effects of MC3/4R to lower blood glucose. To test this
hypothesis, we studied a group of diabetic rats in which
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them to match the amount of food consumed by the
leptin-treated group. Preventing the hyperphagia, how-
ever, did not improve the effectiveness of MTII to lower
blood glucose levels, suggesting that the lack of sustained
antidiabetic effect during chronic MC3/4R activation was
not because of MTII inability to reduce appetite. These
results also conﬁrm our previous observation that the
reduction of food intake in diabetic rats during intracere-
broventricular leptin infusion does not play a major role in
mediating the antidiabetic actions of leptin or in prevent-
ing the cardiovascular alterations associated with uncon-
trolled diabetes (11).
The precise mechanisms by which leptin exerts its
powerful effect on peripheral glucose utilization even in
insulin-deﬁcient diabetic animals are still unclear, al-
though our current study clearly indicates that a functional
MC3/4R plays a crucial role. Previous studies have impli-
cated a role for the autonomic nervous system in mediat-
ing the acute effects of leptin on glucose regulation by
showing that the increased insulin sensitivity observed
during intracerebroventricular injection of single doses of
leptin can be blocked by adrenergic receptor antagonism
(26,27), or that leptin’s ability to suppress liver glucose
production can be prevented by denervation of the vagal
ﬁbers innervating the liver (28). We recently showed that
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receptors failed to attenuate leptin’s ability to restore
euglycemia in STZ-diabetic rats (11). Therefore, it is
possible that leptin-induced sympathetic stimulation of
nonadrenergic receptors may contribute to these effects of
leptin and that the suppression of liver glucose output into
the systemic circulation of diabetic rats may play an
important role in mediating the chronic effects of leptin on
glucose homeostasis, but additional studies are needed to
test these possibilities.
Although our previous study indicates that adrenergic
receptor activation does not mediate the chronic antidia-
betic effects of leptin, 40–50% of the rise in heart rate
and prevention of the bradycardia in STZ-diabetic rats
during leptin infusion was dependent of adrenergic stim-
ulation (11). The mechanisms responsible for the remain-
ing 50–60% of leptin-induced rise in heart rate in diabetic
rats are not well understood. However, the bradycardia
caused by induction of STZ-diabetes is associated with
marked reductions in the intrinsic heart rate (29), which is
the heart rate in the absence of sympathetic and para-
sympathetic inputs to the heart. Moreover, chronic intra-
cerebroventricular leptin infusion completely restored
intrinsic heart rate back to pre-diabetic values (29). We
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DIABETES, VOL. 58, AUGUST 2009 1755have also shown that, similar to leptin, MC3/4R activation
is associated with sustained sympathetic nervous system
activation in nondiabetic rats (30). Whether the lack of
sustained increases in heart rate during MTII in STZ-
diabetic is because of an inability of chronic MC3/4R
activation to cause sustained elevations in cardiac sympa-
thetic activity in a hyperglycemic state or to an inability to
increase intrinsic heart rate remains to be determined.
In summary, leptin has powerful CNS-mediated antidia-
betic effects in insulin-deﬁcient diabetic rats that require
activation of the CNS melanocortin pathway. Leptin also
exerts important cardiovascular effects that require acti-
vation of CNS MC3/4R. However, stimulation of the CNS
MC3/4R alone does not confer the same long-term meta-
bolic and cardiovascular responses as observed with hy-
perleptinemia. These observations indicate that although
leptin-mediated activation of the melanocortin pathway
may be necessary for the antidiabetic and cardiovascular
actions of leptin in this model, it is not sufﬁcient to
completely mimic leptin’s chronic actions. This suggests
that leptin exerts its CNS-mediated effects on appetite,
blood glucose, MAP, and heart rate via a complex system
that likely involves interaction of multiple pathways. Un-
raveling these interactions would contribute to a better
understanding of the CNS control of appetite, glucose
homeostasis, and cardiovascular function and could lead
to the development of novel therapeutic strategies to
treated obesity, metabolic syndrome, diabetes, and cardio-
vascular diseases.
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